Document:

<PAGE>

                                                                     EXHIBIT 4.2

                               CENTEX CORPORATION

                                     Issuer

                                      and

                              JPMORGAN CHASE BANK

                      (formerly The Chase Manhattan Bank)

                                    Trustee

                          INDENTURE SUPPLEMENT NO. 14

                            Dated as of May 5, 2004

                                       to

                                   INDENTURE

                          Dated as of October 1, 1998

                      5.70% Senior Notes due May 15, 2014

<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                 Page
                                                                                                 ----
<S>                                                                                              <C>
ARTICLE ONE  Definitions.......................................................................    1

ARTICLE TWO  TERMS AND ISSUANCE OF THE NOTES...................................................    3
         Section 2.01.     Issuance and Designation............................................    3
         Section 2.02.     Form and Other Terms of Notes; Incorporation of Terms...............    3
         Section 2.03.     Place and Method of Payment.........................................    3

ARTICLE THREE  ADDITIONAL COVENANTS............................................................    4
         Section 3.01.     Limitation on Liens.................................................    4
         Section 3.02.     Limitation on Sale and Lease-Back Transactions......................    6

ARTICLE FOUR  DEFEASANCE.......................................................................    6
         Section 4.01.     Option to Effect Legal Defeasance or Covenant Defeasance............    6
         Section 4.02.     Legal Defeasance....................................................    6
         Section 4.03.     Covenant Defeasance.................................................    7
         Section 4.04.     Conditions to Covenant Defeasance...................................    7

ARTICLE FIVE  MISCELLANEOUS....................................................................    8
         Section 5.01.     Ratification of Indenture...........................................    8
         Section 5.02.     Redemption..........................................................    8
         Section 5.03.     Conflict with Trust Indenture Act...................................    8
         Section 5.04.     Effect of Headings..................................................    8
         Section 5.05.     Counterparts........................................................    8
         Section 5.06.     Severability........................................................    8
         Section 5.07.     Benefits of Indenture Supplement....................................    8
         Section 5.08.     Acceptance of Trusts................................................    9
         Section 5.09.     Governing Law.......................................................    9

EXHIBIT A  -               Form of Note
</TABLE>

                                       i
<PAGE>

            INDENTURE SUPPLEMENT NO. 14 ("Indenture Supplement"), dated as of
May 5, 2004, between CENTEX CORPORATION, a Nevada corporation (together with its
successors and assigns as provided in the Indenture referred to below, the
"Company"), and JPMORGAN CHASE BANK, a New York banking corporation (formerly,
The Chase Manhattan Bank, successor to Chase Bank of Texas, National
Association) (together with its successors in trust thereunder as provided in
the Indenture referred to below, the "Trustee"), as trustee under an Indenture
dated as of October 1, 1998 (the "Indenture").

                             PRELIMINARY STATEMENT

            Section 2.02 of the Indenture provides, among other things, that the
Company may, when authorized by its Board of Directors, and the Trustee may at
any time and from time to time, enter into a series supplement to the Indenture
for the purpose of authorizing one or more Series of Senior Debt Securities and
to specify certain terms of each such Series of Senior Debt Securities. The
Board of Directors of the Company has duly authorized the creation of a Series
of Senior Debt Securities to be known as the Company's 5.70% Senior Notes due
2014 (the "Notes"), and the Company and the Trustee are executing and delivering
this Indenture Supplement in order to provide for the issuance of the Notes.

                                  ARTICLE ONE

                                  Definitions

            Except to the extent such terms are otherwise defined in this
Indenture Supplement or the context clearly requires otherwise, all terms used
in this Indenture Supplement which are defined in the Indenture or the form of
Note attached hereto as Exhibit A, either directly or by reference therein,
shall have the meanings assigned to them therein.

            As used in this Indenture Supplement, the following terms shall have
the following meanings:

CONSOLIDATED NET TANGIBLE ASSETS:

            The term "Consolidated Net Tangible Assets" shall mean the aggregate
amount of assets included on the most recent consolidated balance sheet of the
Company and its subsidiaries, less applicable reserves and other properly
deductible items and after deducting therefrom (a) all current liabilities and
(b) all goodwill, trade names, trademarks, patents, unamortized debt discount
and expense, and other like intangibles, all in accordance with generally
accepted accounting principles consistently applied.

DEPOSITARY:

            The term "Depositary" shall mean, unless otherwise specified by the
Company, The Depository Trust Company, New York, New York, or any successor
thereto registered as a Clearing Agency under the Securities Exchange Act of
1934, as amended, or any successor statute or regulation.

<PAGE>

FUNDED INDEBTEDNESS:

            The term "Funded Indebtedness" shall mean notes, bonds, debentures
or other similar evidences of indebtedness for money borrowed which by their
terms mature at or are extendible or renewable at the option of the obligor to a
date more than 12 months after the date of the creation of such debt.

GLOBAL SECURITY:

            The term "Global Security" shall mean a single Note that is issued
to evidence Notes having identical terms and provisions, which is delivered to
the Depositary or pursuant to instructions of the Depositary and which shall be
registered in the name of the Depositary or its nominee.

INTEREST PAYMENT DATE:

            The term "Interest Payment Date" means the Stated Maturity of an
installment of interest on the Notes.

MATURITY DATE:

            The term "Maturity Date," when used with respect to any Note, shall
mean the date on which the principal of such Note becomes due and payable in
accordance with its terms and the terms of this Indenture as therein or herein
provided, whether at Stated Maturity, upon declaration of acceleration, call for
redemption or otherwise.

NOTEHOLDER; HOLDER:

            The terms "Noteholder" or "Holder" shall mean any Person in whose
name at the time a particular Note is registered in the Senior Debt Security
Register kept for that purpose in accordance with the terms hereof.

REGULAR RECORD DATE:

            The term "Regular Record Date" for the interest payable on any
Interest Payment Date shall mean the day which is fifteen calendar days
immediately prior to such Interest Payment Date, whether or not such day is a
business day.

REDEMPTION DATE:

            The term "Redemption Date" for a Note shall mean the date fixed for
the redemption of such Note in accordance with the provisions of this Indenture
Supplement.

                                       2
<PAGE>

SPECIAL RECORD DATE:

            The term "Special Record Date" for the payment of any defaulted
interest means a date which is not less than ten and not more than fifteen
calendar days immediately preceding the Interest Payment Date of defaulted
interest on such Note established by notice given by first class mail by or on
behalf of the Company to the Holder of such Note not less than fifteen calendar
days prior to such Special Record Date.

STATED MATURITY:

            The term "Stated Maturity" means, when used with respect to any Note
or any installment of interest thereon (including defaulted interest), the date
specified in such Note as the fixed date upon which the principal of such Note
or such installment of interest is due and payable.

                                  ARTICLE TWO

                        Terms and Issuance of the Notes

            Section 2.01. Issuance and Designation. A Series of Senior Debt
Securities which shall be designated as the Company's "5.70% Senior Notes due
2014" shall be executed, authenticated and delivered in accordance with the
provisions of, and shall in all respects be subject to, the terms, conditions
and covenants of, the Indenture and this Indenture Supplement (including the
form of Note set forth in Exhibit A). The aggregate principal amount of the
Notes which may be authenticated and delivered under this Indenture Supplement
shall not, except as permitted by the provisions of the Indenture, exceed
$350,000,000, provided that the Company may, without the consent of the Holders
of the Notes, reopen this Series and issue additional Notes under the Indenture
and this Indenture Supplement in addition to the $350,000,000 of Notes
authorized as of the date hereof.

            Section 2.02. Form and Other Terms of Notes; Incorporation of Terms.
The Notes shall be substantially in the form attached hereto as Exhibit A. The
terms of such Notes are herein incorporated by reference and are part of this
Indenture Supplement.

            Section 2.03. Place and Method of Payment. The place of payment in
respect of the Notes will be at the principal office or agency of the Company in
Dallas, Texas or at the office or place of business of the Trustee or its
successor in trust under the Indenture, which, at the date hereof, is located at
Chase Global Trust, 450 W. 33rd Street, 15th Floor, New York, New York 10001.
Payments in respect of principal or premium, if any, on Notes will be made only
against surrender of such Notes at such office. Payments of interest on each
Interest Payment Date with respect to each Note will be made to the Person in
whose name such Note is registered at the close of business on the Regular
Record Date immediately preceding such Interest Payment Date by U.S. dollar
check drawn on a bank in the City of New York or, for Holders of at least
$1,000,000 of Notes, by wire transfer to a dollar account maintained by the
payee with a bank in the United States; provided that a written request from
such Holder to such effect

                                       3
<PAGE>

designating such account is received by the Trustee or the Paying Agent no later
than 30 calendar days preceding such Interest Payment Date. Unless such
designation is revoked, any such designation made by such Holder with respect to
such Note payable to such Holder will remain in effect with respect to any
further interest payments with respect to such Note payable to such Holder. The
Company will pay any administrative costs imposed by banks in connection with
making interest payments by wire transfer.

            So long as the Depositary continues to make its "Same-Day Funds
Settlement System" available to the Company, payments due on Notes represented
by a Global Security registered in the name of the Depositary or its nominee
will be made in immediately available funds to the Depositary or its nominee, as
the case may be, as the registered owner of the Global Security representing
such Notes. The Company expects that the Depositary or its nominee, upon receipt
of any payment, will credit immediately participants' accounts with payments in
same-day funds in amounts proportionate to their respective beneficial interests
in such payments, as shown on the records of the Depositary or its nominee. The
Company also expects that payments by participants and indirect participants to
owners of beneficial interests in such Global Security held through such Persons
will be governed by standing instructions and customary practices, as is now the
case with securities registered in the name of nominees for such customers, and
will be the responsibility of such participants and indirect participants.

                                 ARTICLE THREE

                              Additional Covenants

            Section 3.01. Limitation on Liens. The following provisions shall
apply to the Notes:

            (a)   The Company will not itself, and will not permit any of its
      subsidiaries (other than Centex Financial Services, Inc. and its
      subsidiaries) to, issue, assume or guarantee any indebtedness for borrowed
      money ("Indebtedness") if such borrowed money is secured by a mortgage,
      pledge, security interest, lien or other encumbrance (any such mortgage,
      pledge, security interest, lien or other encumbrance being hereinafter in
      this Section 3.01 referred to as a "Lien") on or with respect to any of
      the properties or assets of the Company or any such subsidiary or on any
      shares of capital stock or other equity interests of any subsidiary that
      owns properties or assets (other than Centex Financial Services, Inc. and
      its subsidiaries), whether, in each case, owned at the date of this
      Indenture Supplement or thereafter acquired, unless the Company makes
      effective provision whereby the Notes are secured by such Lien equally and
      ratably with any and all other borrowed money thereby secured; provided,
      however, that the foregoing restrictions shall not be applicable to:

                  (i)   any Lien existing on any of the Company's properties or
            assets or shares of capital stock or other equity interests at the
            date of this Indenture Supplement;

                                       4
<PAGE>

                  (ii)  any Lien created by a subsidiary of the Company in favor
            of the Company or any wholly-owned subsidiary;

                  (iii) any Lien on any property or asset of any corporation or
            other entity (or on any accession or improvement to such asset or
            any proceeds thereof) existing at the time such corporation or other
            entity becomes a subsidiary of the Company or is merged or
            consolidated with or into the Company or any of its subsidiaries;

                  (iv)  any Lien on any property or asset existing at the time
            of acquisition thereof (or on any accession or improvement to such
            property or asset or any proceeds thereof) by the Company or any of
            its subsidiaries;

                  (v)   any Lien on any property or asset (or on any accession
            or improvement to such property or asset or any proceeds thereof)
            securing Indebtedness incurred or assumed for the purpose of
            financing all or any part of the cost of acquiring such property or
            asset or the making of any improvement thereof; provided that such
            Lien attaches to such property or asset concurrently with or within
            180 days after the acquisition thereof or the making of such
            improvement;

                  (vi)  any Lien incurred in connection with pollution control,
            industrial revenue or any similar financing;

                  (vii) any Lien arising out of the refinancing, extension,
            renewal or replacement of any of the Liens permitted by any of
            clauses (i) through (vi) above; provided that the principal amount
            of the Indebtedness secured by the Lien being refinanced, extended,
            reviewed or replaced is not increased and is not secured by any
            additional properties or assets; and

                  (viii) any Lien imposed by law.

            (b)   Notwithstanding the provisions of subsection (a) of this
      Section 3.01, the Company or any of its subsidiaries may issue, assume or
      guarantee Indebtedness secured by a Lien which would otherwise be subject
      to the foregoing restrictions in an aggregate amount which, together with
      all other such secured borrowings of the Company and its subsidiaries and
      the Attributable Debt (as defined below) in respect of Sale and Lease-Back
      Transactions (as defined in Section 3.02) existing at such time (other
      than Sale and Lease-Back Transactions not subject to the limitation
      contained in Section 3.02), does not at the time exceed twenty percent
      (20%) of the Consolidated Net Tangible Assets of the Company and its
      subsidiaries, as shown on the audited consolidated balance sheet contained
      in the latest annual report to stockholders of the Company. The term
      "Attributable Debt" as used in this paragraph shall mean, as of any
      particular time, the present value of the obligation of a lessee for
      rental payments during the remaining term of any lease (including any
      period for which such lease has been extended or may, at the option of the
      lessor, be extended).

                                       5
<PAGE>

            Section 3.02. Limitation on Sale and Lease-Back Transactions. The
Company will not, nor will it permit any of its subsidiaries to, enter into any
arrangement with any Person (other than the Company) providing for the leasing
by the Company or a subsidiary of any of its properties or assets (except for
temporary leases for a term of not more than three (3) years and except for
sales and leases of model homes), which property or asset has been or is to be
sold or transferred by the Company or such subsidiary to such Person (herein
referred to as a "Sale and Lease-Back Transaction"), unless (a) the net proceeds
to the Company or such subsidiary from such sale or transfer equal or exceed the
fair value (as determined by the Board of Directors, the Chairman of the Board,
the Vice Chairman, the President or the principal financial officer of the
Company) of the property or asset so leased, (b) the Company or such subsidiary
would be entitled to incur Indebtedness secured by a Lien on the property or
asset to be leased pursuant to Section 3.01, (c) the Company shall, and in any
such case the Company covenants that it will, apply an amount equal to the fair
value (as determined by the Board of Directors, the Chairman of the Board, the
Vice Chairman, the President or the principal financial officer of the Company)
of the property or asset so leased to the retirement (other than any mandatory
retirement), within 180 days of the effective date of any such Sale and
Lease-Back Transaction, of Funded Indebtedness of the Company, (d) such Sale and
Lease-Back Transaction relates to a sale which occurred within 180 days from the
date of acquisition of such property or asset by the Company or a subsidiary or
the date of the completion of construction or commencement of full operations on
such property, whichever is later, or (e) such transaction was consummated prior
to the date of this Indenture Supplement.

                                  ARTICLE FOUR

                                   Defeasance

            Section 4.01. Option to Effect Legal Defeasance or Covenant
Defeasance. The Company may, at any time, with respect to the Notes, elect to
have either Section 13.01 of the Indenture or Section 4.03 of this Indenture
Supplement be applied to all outstanding Notes upon compliance with the
conditions set forth in Article Thirteen of the Indenture and below in this
Article Four.

            Section 4.02. Legal Defeasance. Upon the Company's exercise under
Section 4.01 of the option applicable to Section 13.01 of the Indenture, the
Company may terminate its obligations under the Notes, the Indenture and this
Indenture Supplement by complying with the terms and conditions of Section 13.01
of the Indenture; provided, however, that the Opinion of Counsel delivered to
the Trustee will also state that either (A) the Company has received from, or
there has been published by, the Internal Revenue Service, a ruling or (B) since
the date hereof, there has been a change in the applicable federal income tax
law, in either case to the effect that, and based thereon such Opinion of
Counsel shall confirm that, the Holders of the outstanding Notes will not
recognize income, gain or loss for federal income tax purposes as a result of
such defeasance and will be subject to federal income tax on the same amounts,
in the same manner and at the same times as would have been the case if such
defeasance had not occurred.

                                       6
<PAGE>

            Section 4.03. Covenant Defeasance. Upon the Company's exercise under
Section 4.01 of the option applicable to this Section 4.03, the Company shall be
released from its obligations under the covenants contained in Article Three of
this Indenture Supplement with respect to the outstanding Notes on and after the
date the conditions set forth below are satisfied ("Covenant Defeasance"), and
the Notes shall thereafter be deemed not "outstanding" for the purposes of any
direction, waiver, consent or declaration or act of Holders (and the
consequences of any thereof) in connection with such covenants, but shall
continue to be deemed "outstanding" for all other purposes hereunder (it being
understood that such Notes shall not be deemed outstanding for accounting
purposes). For this purpose, such Covenant Defeasance means that, with respect
to the outstanding Notes, the Company may omit to comply with and shall have no
liability in respect of any term, condition or limitation set forth in any such
covenant, whether directly or indirectly, by reason of any reference elsewhere
herein to any such covenant or by reason of any reference in any such covenant
to any other provision herein or in any other document and such omission to
comply shall not constitute a Default or an Event of Default, but, except as
specified above, the remainder of the Indenture and such Notes shall be
unaffected thereby. In addition, the Company's exercise under Section 4.01 of
the option applicable to this Section 4.03 shall not constitute an Event of
Default.

            Section 4.04. Conditions to Covenant Defeasance. The following shall
be the conditions to the application of Section 4.03 to the outstanding Notes:

            (1)   the Company shall irrevocably have deposited or caused to be
      deposited with the Trustee under the terms of an irrevocable trust
      agreement in form and substance satisfactory to the Trustee, as trust
      funds in trust solely for the benefit of the Holders of such Notes for
      that purpose, money or direct non-callable obligations of, or non-callable
      obligations guaranteed by, the United States of America for the payment of
      which guarantee or obligation the full faith and credit of the United
      States is pledged ("U.S. Government Obligations") maturing as to principal
      and interest in such amounts and at such times as are sufficient, as
      verified in a Certificate of a Firm of Independent Public Accountants,
      without consideration of any reinvestment of such interest, to pay
      principal of and interest on the outstanding Notes to maturity or
      redemption as the case may be, provided that the Trustee or any paying
      agent shall have been irrevocably instructed to apply such money or the
      proceeds of such U.S. Government Obligations to the payment of said
      principal and interest with respect to the Notes. The Company may make an
      irrevocable deposit pursuant to this Section 4.04 only if at such time the
      Company shall have delivered to the Trustee and any such paying agent an
      Officers' Certificate and an Opinion of Counsel, each stating that all
      conditions herein precedent to the satisfaction and discharge of this
      Indenture have been complied with and the Opinion of Counsel further
      states that the making of such deposit (i) does not contravene or violate
      any provision of any indenture, mortgage, loan agreement or other similar
      agreement known to such counsel to which the Company is a party or by
      which it or any of its property is bound, (ii) does not require
      registration by the deposit referred to above under the Investment Company
      Act of 1940, as amended, and (iii) to the effect that the Holders of the
      outstanding Notes will not recognize income, gain or loss for federal
      income tax purposes as a result of such defeasance and will be subject to
      federal income tax in the

                                       7
<PAGE>

      same amount, in the same manner and at the same times as would have been
      the case if such defeasance had not occurred.

            (2)   Notwithstanding the foregoing paragraph, the Company's
      obligations in Sections 2.06, 2.08, 5.01, 5.02, 5.05, 6.01, 8.06, 8.10,
      13.04 and 13.05 of the Indenture shall survive until the Notes are no
      longer outstanding. Thereafter, the Company's obligations in Sections
      8.06, 13.04 and 13.05 of the Indenture shall survive.

                                  ARTICLE FIVE

                                 Miscellaneous

            Section 5.01. Ratification of Indenture. As supplemented by this
Indenture Supplement, the Indenture is in all respects ratified and confirmed
and the Indenture as so supplemented by this Indenture Supplement shall be read,
taken and construed as one and the same instrument.

            Section 5.02. Redemption. Notwithstanding anything contained in the
Indenture, the Company may redeem any of the Notes upon the terms and conditions
contained in the Notes directly or indirectly from or in anticipation of money
borrowed having an interest cost to the Company of less than the interest rate
applicable to the Notes.

            Section 5.03. Conflict with Trust Indenture Act. If any provision
hereof limits, qualifies or conflicts with another provision hereof which is
required to be included in this Indenture Supplement by any of the provisions of
the Trust Indenture Act, such required provisions shall control.

            Section 5.04. Effect of Headings. The article and section headings
herein are included for convenience only and shall not affect the construction
hereof.

            Section 5.05. Counterparts. This Indenture Supplement may be
executed in any number of counterparts, each of which shall be an original; but
such counterparts shall together constitute but one and the same instrument.

            Section 5.06. Severability. In case any provision of this Indenture
Supplement or in the Notes shall be found invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

            Section 5.07. Benefits of Indenture Supplement. Nothing in this
Indenture Supplement or in the Notes, express or implied, shall give to any
Person, other than the parties hereto and their successors hereunder and the
Holders, any benefit or any legal or equitable right, remedy or claim under this
Indenture Supplement.

                                       8
<PAGE>

            Section 5.08. Acceptance of Trusts. The Trustee hereby accepts the
trusts in this Indenture Supplement declared and provided, upon the terms and
conditions herein and in the Indenture set forth.

            Section 5.09. Governing Law. This Indenture Supplement and each Note
issued hereunder shall be deemed to be a contract made under the laws of the
State of Texas, and for all purposes shall be construed in accordance with the
laws of said State.

                                       9
<PAGE>

            IN WITNESS WHEREOF, the Company and the Trustee have caused this
Indenture Supplement to be duly executed by their respective officers thereunto
duly authorized and their respective seals duly attested to be hereunto affixed
all as of the day and year first above written.

                                    CENTEX CORPORATION

[SEAL]

                                    By: /s/ Gail Peck
                                        ----------------------------------
                                    Name:  Gail Peck
                                    Title: Vice President and Treasurer

Attest:

/s/ Paul Johnston
-----------------------------
Name:  Paul Johnston
Title: Assistant Secretary

                                    JPMORGAN CHASE BANK
                                    (f/k/a The Chase Manhattan Bank), as Trustee

[SEAL]

                                    By: /s/ Donna Edmundson
                                        ----------------------------------
                                        Name:  Donna Edmundson
                                        Title: Vice President

Attest:

/s/ Frank W. McCreary
---------------------------------
Name: Frank W. McCreary
Title: Trust Officer

                                       10
<PAGE>

STATE OF TEXAS       )
                     )
COUNTY OF DALLAS     )

            BEFORE ME, the undersigned authority, a Notary Public in and for
said state, on this day personally appeared Paul Johnston and Gail Peck, known
to me to be the persons and officers whose names are subscribed to the foregoing
instrument and acknowledged to me that the same was the act of the said CENTEX
CORPORATION, a Nevada corporation, and that they executed the same as the act of
said corporation for the purposes and consideration therein expressed, and in
the capacity therein stated.

            GIVEN UNDER MY HAND AND SEAL OF OFFICE, this 5th day of May, 2004.

                                     /s/ Candie C. Nelson
                                     -------------------------------------------
                                     Notary Public in and for the State of Texas

                                     Candie C. Nelson
                                     -------------------------------------------
                                     Printed Name of Notary Public

My commission expires:

1/18/2005
------------------------

STATE OF TEXAS      )
                    )
COUNTY OF HARRIS    )

            BEFORE ME, the undersigned authority, a Notary Public in and for
said state, on this day personally appeared Frank W. McCreary and Donna
Edmundson, known to me to be the persons and officers whose names are subscribed
to the foregoing instrument and acknowledged to me that the same was the act of
the said JPMORGAN CHASE BANK, a New York banking corporation, and that they
executed the same as the act of said New York banking corporation for the
purposes and consideration therein expressed, and in the capacity therein
stated.

            GIVEN UNDER MY HAND AND SEAL OF OFFICE, this 5th day of May, 2004.

                                     /s/ Luis Bustamante
                                     -------------------------------------------
                                     Notary Public in and for the State of Texas

                                     /s/ Luis Bustamante
                                     -------------------------------------------
                                     Printed Name of Notary Public

My commission expires:

10/23/2004
------------------------

                                       11
<PAGE>

                                       12
<PAGE>

                                                                       EXHIBIT A

                             [FORM OF FACE OF NOTE]

      [the following legend shall appear on the face of each global Note:

      THIS SECURITY IS A Global SECURITY WITHIN THE MEANING OF THE INDENTURE
HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A
NOMINEE OF A DEPOSITARY. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED
IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN the
LIMITED CIRCUMSTANCES DESCRIBED IN the INDENTURE, AND NO TRANSFER OF THIS
SECURITY (OTHER THAN A TRANSFER OF THIS SECURITY AS A WHOLE BY THE DEPOSITARY TO
A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY
OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN LIMITED
CIRCUMSTANCES.

            UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION, 55 WATER STREET, NEW YORK, NEW
YORK ("DTC"), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE
OR PAYMENT, AND ANY NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO., OR IN
SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY
PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR
VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

            UNLESS AND UNTIL THIS GLOBAL NOTE IS EXCHANGED IN WHOLE OR IN PART
FOR THE INDIVIDUAL NOTES REPRESENTED HEREBY, THIS GLOBAL NOTE MAY NOT BE
TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY
OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR
A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.]

<PAGE>

                                                         CUSIP No.:_____________

                                                               PRINCIPAL AMOUNT:

REGISTERED NO._____________                                 $___________________

                               CENTEX CORPORATION

                           ___% SENIOR nOTES DUE 20__

            Centex Corporation, a corporation duly organized and existing under
the laws of the State of Nevada (herein called the "Company," which term
includes any successor Person under the Indenture hereinafter referred to) for
value received, hereby promises to pay to Cede & Co., or registered assigns, the
principal sum of __________ United States Dollars on _________, 20__ and to pay
interest thereon, in such coin or currency commencing __________, 2004 and
continuing semi-annually thereafter on ______ and ______ of each year, from
__________, 2004 or from the most recent Interest Payment Date to which interest
has been paid or duly provided for, at the rate per annum provided in the title
hereof, until the principal hereof is paid or made available for payment. The
interest so payable and punctually paid or duly provided for on any Interest
Payment Date will, as provided in the Indenture, be paid to the Person in whose
name this Note (or one or more predecessor Notes) is registered at the close of
business on the Regular Record Date which shall be ________ or ________ (whether
or not a business day), as the case may be, next preceding such Interest Payment
Date; provided, however, that interest payable on the Maturity Date or, if
applicable, upon redemption, shall be payable to the Person to whom principal
shall be payable. Except as otherwise provided in the Indenture, any such
interest not so punctually paid or duly provided for will forthwith cease to be
payable to the Holder on such Regular Record Date and shall be paid on the date
fixed therefor by the Company to the Person in whose name this Note is
registered at the close of business on a Special Record Date for the payment of
such defaulted interest to be fixed by the Company, notice whereof shall be
given to Noteholders not less than fifteen calendar days prior to such Special
Record Date.

            The Indenture and the Notes shall be governed by, and construed in
accordance with, the laws of the State of Texas.

            REFERENCE IS HEREBY MADE TO THE FURTHER PROVISIONS OF THIS NOTE SET
FORTH IN FULL ON THE REVERSE HEREOF, WHICH FURTHER PROVISIONS SHALL FOR ALL
PURPOSES HAVE THE SAME EFFECT AS IF SET FORTH IN FULL AT THIS PLACE.

            Unless the certificate of authentication hereon has been executed by
the Trustee referred to on the reverse hereof, directly or through a duly
appointed and authorized authenticating agent, by manual or facsimile signature
of an authorized signatory, this Note shall not be entitled to any benefit under
the Indenture or be valid or obligatory for any purpose.

                                       2
<PAGE>

            IN WITNESS WHEREOF, the Company has caused this instrument to be
duly executed.

                                      CENTEX CORPORATION

[SEAL]

                                      By:_____________________________
                                         Name:
                                         Title:

ATTEST:

_____________________________
Name:
Title:

TRUSTEE'S CERTIFICATE
    OF AUTHENTICATION

This is one of the Senior Debt Securities referred to in the within-mentioned
Indenture.

JPMORGAN CHASE BANK
(f/k/a The Chase Manhattan Bank), as Trustee

By:___________________________
   Authorized Signatory

                                       3
<PAGE>

                           [FORM OF REVERSE OF NOTE]

            This Note is one of a duly authorized issue of Senior Debt
Securities of the Company designated as its ___% Senior Notes due 20__ (herein
called the "Notes"), issued and to be issued in one or more Series under an
Indenture dated as of October 1, 1998 (herein called the "Indenture") between
the Company and JPMorgan Chase Bank (f/k/a The Chase Manhattan Bank), as Trustee
(herein called the "Trustee," which term includes any successor Trustee under
the Indenture), to which Indenture and all indentures supplemental thereto
(including the Indenture Supplement dated as of _______ ___, 2004 which
authorizes the Notes) reference is hereby made for a statement of the respective
rights, limitations of rights, duties and immunities thereunder of the Company,
the Trustee and the Holders of the Notes, and of the terms upon which the Notes
are, and are to be, authenticated and delivered.

            All terms used in this Note which are defined in the Indenture or in
any indenture supplemental thereto but are not defined in this Note shall have
the meanings assigned to them in the Indenture or in any indenture supplemental
thereto.

            The indebtedness evidenced by the Notes is, to the extent and in the
manner provided in the Indenture and the Indenture Supplement, senior in right
of payment to certain indebtedness of the Company.

            Interest on this Note will be payable on the Interest Payment Date
or Interest Payment Dates as specified on the face hereof and, in either case,
on the Maturity Date. Unless otherwise specified on the face hereof, payments on
this Note with respect to any particular Interest Payment Date or the Maturity
Date will include interest accrued from and including ______________, 2004, or
from and including the most recent Interest Payment Date to which interest has
been paid or duly provided for, to but excluding the particular Interest Payment
Date or the Maturity Date. Interest on this Note will be computed and paid on
the basis of a 360-day year of twelve 30-day months.

            If an Interest Payment Date or the Maturity Date for this Note falls
on a day that is not a business day, payment of principal, premium, if any, and
interest to be made on such day with respect to this Note will be made on the
next succeeding day that is a business day with the same force and effect as if
made on the due date, and no additional interest will be payable on the date of
payment for the period from and after the due date as a result of such delayed
payment.

            The Notes will be redeemable, in whole or in part, from time to time
at the option of the Company, on any date (a "Redemption Date") at a redemption
price equal to the greater of (a) 100% of the principal amount of the Notes to
be redeemed and (b) the sum of the present values of the Remaining Scheduled
Payments (as hereinafter defined) of principal and interest thereon (exclusive
of interest accrued to such Redemption Date) discounted to such Redemption Date
on a semiannual basis (assuming a 360-day year consisting of twelve 30-day
months) at the Treasury Rate (as hereinafter defined) plus ___ basis points,
plus accrued and unpaid interest on the principal amount being redeemed to such
Redemption Date; provided, however, that installments of interest on the Notes
that are due and payable on an Interest Payment Date falling on or prior to the
relevant Redemption Date shall be payable to the Holders of such Notes,

                                       4
<PAGE>

registered as such at the close of business on the relevant Regular Record Date
or Special Record Date, as the case may be, according to their terms and the
provisions of the Indenture.

            "Comparable Treasury Issue" means the United States Treasury
security selected by the Independent Investment Banker (as hereinafter defined)
as having a maturity comparable to the remaining term of the Notes to be
redeemed that would be utilized, at the time of selection and in accordance with
customary financial practice, in pricing new issues of corporate debt securities
of comparable maturity to the remaining term of the Notes.

            "Comparable Treasury Price" means, with respect to any Redemption
Date, (1) the average of the bid and asked prices for the Comparable Treasury
Issue (expressed in each case as a percentage of its principal amount) on the
third business day preceding such Redemption Date, as set forth in the daily
statistical release (or any successor release) published by the Federal Reserve
Bank of New York and designated "Composite 3:30 p.m. Quotations for U.S.
Government Securities" or (2) if such release (or any successor release) is not
published or does not contain such prices on such business day, (A) the average
of the Reference Treasury Dealer Quotations (as hereinafter defined) for such
Redemption Date, after excluding the highest and lowest such Reference Treasury
Dealer Quotations, or (B) if the Trustee obtains fewer than four such Reference
Treasury Dealer Quotations, the average of all such Quotations.

            "Independent Investment Banker" means Citigroup Global Markets Inc.
and J.P. Morgan Securities Inc.

            "Reference Treasury Dealer" means Citigroup Global Markets Inc. and
J.P. Morgan Securities Inc. and their respective successors and, at the option
of the Company, other primary U.S. government securities dealers in New York
City selected by the Company.

            "Reference Treasury Dealer Quotations" means, with respect to the

            Reference Treasury Dealer and any Redemption Date, the average, as
determined by the Trustee, of the bid and asked prices for the Comparable
Treasury Issue (expressed in each case as a percentage of its principal amount)
quoted in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m.,
New York City time, on the third business day preceding such Redemption Date.

            "Remaining Scheduled Payments" means, with respect to any Note, the
remaining scheduled payments of the principal thereof to be redeemed and
interest thereon that would be due after the related Redemption Date but for
such redemption; provided, however, that, if such Redemption Date is not an
Interest Payment Date with respect to such Note, the amount of the next
succeeding scheduled interest payment thereon will be reduced by the amount of
interest accrued thereon to such Redemption Date.

            "Treasury Rate" means, with respect to any Redemption Date for the
Notes, the rate per annum equal to the semi-annual equivalent yield to maturity
of the Comparable Treasury Issue, calculated using a price for the Comparable
Treasury Issue (expressed as a percentage of its principal amount) equal to the
Comparable Treasury Price for such Redemption Date.

            Notice of any redemption by the Company will be mailed at least 30
days but not more than 60 days before any Redemption Date to each Holder of
Notes to be redeemed. If less

                                       5
<PAGE>

than all the Notes are to be redeemed at the option of the Company, the Trustee
shall select the Notes to be redeemed in whole or in part by random lot.

            This Note is not subject to a sinking fund. Holders of Notes will
not be permitted to require the Company to redeem or repurchase the Notes at
their option.

            In case an Event of Default shall have occurred and be continuing
with respect to the Notes, the principal hereof may be declared, and upon such
declaration shall become, due and payable, in the manner, with the effect and
subject to the conditions provided in the Indenture. The Indenture provides that
in certain events such declaration and its consequences may be waived by the
Holders of a majority in aggregate principal amount of the Notes then
outstanding. An Event of Default with respect to the Senior Debt Security of any
other Series issued under the Indenture, including the failure to make any
payment of principal or interest with respect thereto when and as due, will not
necessarily be an Event of Default with respect to the Notes.

            The Indenture, as supplemented by the Indenture Supplement relating
to the Notes, contains provisions permitting the Company and the Trustee, with
the consent of the Holders of not less than a majority in aggregate principal
amount of the Notes at the time outstanding, evidenced as in the Indenture
provided, to execute supplemental indentures adding any provisions to or
changing in any manner or eliminating any of the provisions of the Indenture or
of any supplemental indenture or modifying in any manner the rights of the
Holders of the Notes; provided, however, that no such supplemental indenture
shall (i) extend the fixed maturity of any Notes, or reduce the principal amount
thereof, or reduce the rate or extend the time of payment of interest thereon,
or reduce any premium payable on the redemption thereof, without the consent of
the Holder of each Note so affected, or (ii) reduce the aforesaid percentage of
Notes, the consent of the Holders of which is required for any such supplemental
indenture, without the consent of the Holders of all Notes then outstanding. The
Indenture also provides that the Holders of a majority in aggregate principal
amount of the Notes at the time outstanding may on behalf of the Holders of all
the Notes waive any past default under the Indenture and its consequences,
except a default in the payment of the principal of or premium, if any, or
interest on any of the Notes. Any such consent or waiver by the Holder of this
Note (unless revoked as provided in the Indenture) shall be conclusive and
binding upon such Holder and upon all future Holders and owners of this Note and
of any Note issued in exchange or substitution herefor, whether or not any
notation of such consent or waiver is made upon this Note.

            As set forth in, and subject to, the provisions of the Indenture, no
Holder of any Note will have any right to institute any proceeding with respect
to the Indenture or for any remedy thereunder, unless such Holder shall have
previously given to the Trustee written notice of default in respect of the
Notes and of the continuance thereof, and unless the Holders of not less than 25
percent in aggregate principal amount of the Notes then outstanding shall have
made written request upon the Trustee to institute such action or proceedings in
its own name as Trustee hereunder and shall have furnished to the Trustee such
reasonable indemnity as it may require, and the Trustee shall have failed to
institute such proceeding within 60 calendar days; provided, however, that such
limitations do not apply to a suit instituted by the Holder hereof for

                                       6
<PAGE>

the enforcement of payment of the principal of and any premium or interest on
this Note on or after the respective due dates expressed herein.

            As provided in the Indenture and subject to certain limitations
therein set forth, the transfer of this Note is registrable in the Senior Debt
Security Register upon surrender of this Note for registration of transfer at
the office or agency maintained by the Company for such purpose, duly endorsed
by, or accompanied by a written instrument of transfer in form satisfactory to
the Company and the Senior Debt Security Registrar duly executed by the Holder
hereof or his attorney duly authorized in writing, and thereupon one or more new
Notes, of authorized denominations and for the same aggregate principal amount,
will be issued to the designated transferee or transferees.

            The Notes are issued only in registered form without coupons in
denominations of $1,000 and any integral multiple thereof. A Holder may transfer
or exchange Notes in accordance with the Indenture.

            No service charge shall be made for any such registration of
transfer or exchange, but the Company may require payment of a sum sufficient to
cover any tax or other governmental charge payable in connection therewith.

            No reference herein to the Indenture and no provision of this Note
or of the Indenture shall alter or impair the obligation of the Company, which
is absolute and unconditional, to pay the principal of, premium, if any, and
interest on this Note at the times, places and rates, and in the coin or
currency, herein prescribed.

            The Indenture, as supplemented by the Indenture Supplement relating
to the Notes, contains provisions for legal defeasance at any time of the entire
indebtedness of this Note or defeasance of certain restrictive covenants with
respect to this Note, in each case upon compliance by the Company with certain
conditions set forth therein.

            The Company, the Trustee, any paying agent and any Senior Debt
Security Registrar for the Notes may deem and treat the Holder hereof as the
absolute owner of this Note (whether or not this Note shall be overdue and
notwithstanding any notation of ownership or other writing hereon made by anyone
other than the Company or any such Senior Debt Security Registrar), for the
purpose of receiving payment hereof or on account hereof and for all other
purposes, and neither the Company nor the Trustee nor any paying agent nor any
such Senior Debt Security Registrar shall be affected by any notice to the
contrary.

            No recourse shall be had for the payment of the principal of, or
premium, if any, or interest on, this Note, or for any claim based hereon or
otherwise in respect hereof, or based on or in respect of the Indenture or any
indenture supplemental thereto, against any incorporator, stockholder, officer
or director, as such, past, present or future, of the Company or of any
successor corporation, whether by virtue of any constitution, statute or rule of
law, or by the enforcement of any assessment or penalty or otherwise, all such
liability being, by the acceptance hereof and as part of the consideration for
the issue hereof, expressly waived and released.

                                       7
<PAGE>

                                 ABBREVIATIONS

            The following abbreviations, when used in the inscription of the
face of this instrument, shall be construed as though they were written out in
full according to applicable laws or regulations:

          TEN COM                           =    as tenants in common
          TEN ENT                           =    as tenants by the entireties
          JT TEN                            =    as joint tenants with right of
                                                 survivorship and not as tenants
                                                 in common
          UNIF GIFT MIN ACT                 =    under Uniform Gifts to Minors
                                                 Act
                                                 (Cust)                  (Minor)
                                                 State

                      Additional abbreviations may also be
                       used though not in the above list.

            FOR VALUE RECEIVED the undersigned hereby sell(s) assign(s) and
transfer(s) unto

PLEASE INSERT SOCIAL SECURITY OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE

______________________________

______________________________

Please print or typewrite name and address including postal zip code of assignee

____________________________________________________________

____________________________________________________________

____________________________________________________________

the within Note and all rights thereunder, hereby irrevocably constituting and
appointing ________________________________________ attorney to transfer said
note on the books of the Company, with full power of substitution in the
premises.

Dated:__________________________          ___________________________________

                                          NOTICE: The signature(s) to this
                                          assignment must correspond with the
                                          name(s) as written upon the face of
                                          the within instrument in every
                                          particular, without alteration or
                                          enlargement or any change whatever.
                                          The signature(s) must be guaranteed by
                                          an "eligible guarantor institution"
                                          that is a member or participant in the
                                          Securities Transfer Agents Medallion
                                          Program, the Stock Exchange Medallion
                                          Program or the New York Stock
                                          Exchange, Inc. Medallion Program.

                                       8<PAGE>
                                                                   EXHIBIT 10.77

                        TERMINATION AGREEMENT AND RELEASE

         THIS TERMINATION AGREEMENT AND RELEASE is dated as of March 12, 2004 by
and between Richard J. Lane, an individual residing at 3840 Windmill Lake Road,
Weston, Florida 33332, his heirs, executors, administrators and assigns
("Lane"), and Andrx Corporation, a Delaware corporation with principal offices
at 4955 Orange Drive, Davie, Florida 33314 ("Andrx").

         NOW, THEREFORE, in consideration of the mutual covenants and
undertakings set forth herein, the parties agree as follows:

         1. TERMINATION OF EMPLOYMENT. Effective as of February 3, 2004 (the
"Termination Date"), Lane's employment with Andrx terminated, and Lane ceased
serving as an officer and director of Andrx and each of Andrx's subsidiaries.
Effective as of the Effective Date (as defined herein), the Employment Agreement
between Lane and Andrx, dated as of June 3, 2002 (the "Employment Agreement"),
is terminated and shall be of no further force and effect.

         2. RECEIPT OF CERTAIN PAYMENTS. Lane acknowledges receipt of all base
salary, car allowance and other benefits due him through the Termination Date.

         3. SEVERANCE AND OTHER PAYMENTS. Subject to the terms and provisions of
this Agreement and Release, and provided that Lane does not revoke this
Agreement and Release during the Revocation Period (as defined in Paragraph 13)
or otherwise, Andrx shall make the following payments to Lane:

                 (a) Andrx shall make a cash payment to or on behalf of Lane of
$1,701,163 on or before the "Effective Date" (as defined in Paragraph 13.). Such
payment shall be comprised of:

                           i) $1,061,297 in severance payments by check or wire
transfer directly to Lane; and

<PAGE>

                           ii) the deposit by Andrx on Lane's behalf of $539,866
in withholding taxes on the value of the consideration paid to Lane hereunder.

                           iii) Andrx shall remit an additional $100,000 to or
on behalf of Lane as follows: The amount of the withholding tax set forth in
Paragraph 3(a)(ii) above is calculated on a tax value of $26.01 per share for
the 16,667 Shares to be issued to Lane pursuant to Paragraph 4 below. In the
event the closing price of Andrx Common Stock is greater than $26.01 per share
on the Effective Date, then Andrx shall make an additional tax withholding
payment (the "Additional Withholding Payment") on behalf of Lane in an amount
equal to the product of the following formula: (closing price on the Effective
Date, minus $26.01) x (16,667) x (.25). Andrx will remit the positive
difference, if any, between the aforesaid $100,000 and the Additional
Withholding Payment to Lane.

                  For purposes of illustration only, if the closing price on the
Effective Date is $29.01, then $29.01 - $26.01 = $3; $3 x 16,667 = $50,000;
$50,000 x .25 = $12,500.25. Thus, Andrx would make an Additional Withholding
Payment of $12,500.25 and remit $87,499.75 to Lane.

                  (b) Andrx shall make the following additional payments to or
on behalf of Lane:

                           i) $1,000.00 per month for 17 consecutive months,
commencing on March 31, 2004, and ending on July 31, 2005, for a total payment
of $17,000, which shall be denominated as an automobile allowance and is payable
directly to Lane on the last day of each month;

                           ii) $142.58 per month for 17 consecutive months,
commencing on March 31, 2004, and ending on July 31, 2005, for a total payment
of $2,423, to cover premiums for medical and dental insurance. Such payments are

                                      -2-
<PAGE>

subject to Lane's execution and delivery to Andrx of a COBRA election form, and
are payable by Andrx directly to the insurer on Lane's behalf;

                           iii) provided that Lane remains a member of Weston
Hills Country Club ("Club"), Andrx shall pay membership dues on behalf of Lane
of $5,378 for the period October 2004 through July 2005, directly to the Club
when due, subject to Lane's timely delivery of the invoice therefor to Andrx.
Lane acknowledges that Andrx has previously paid membership dues for the Club on
his behalf for the period August 2003 through September 2004. Lane further
acknowledges and agrees that all Club charges, costs and expenses other than
payment of the aforementioned dues remain solely his obligation.

         4. RESTRICTED STOCK UNITS ("RSU") AND OPTIONS.

                  Under the Employment Agreement and in accordance with the
Restricted Stock Unit Award Agreement, attached hereto as Exhibit I, 100,000
Restricted Stock Units ("RSU") were granted to Lane. Each RSU represents the
right to acquire one share of Andrx Corporation - Andrx Group common stock, par
value $0.001 per share ("Common Stock"). In accordance with Sections 8.1(f) and
5.2(c) of the Employment Agreement as of the Termination Date, Lane's right to
acquire 16,667 shares of Common Stock ("Shares") vested. The remaining RSU's
granted to Lane under the Employment Agreement have not vested and are
terminated and are of no further force and effect. Lane hereby exercises his
right to acquire the 16,667 Shares. On the Effective Date, Andrx shall instruct
its transfer agent to issue and deliver to Lane a certificate evidencing 16,667
Shares.

         5. STOCK OPTIONS.

                  (a) On May 18, 2002, in accordance with the Stock Option
Agreement attached hereto as Exhibit II, Lane was granted options to purchase
500,000 shares of Common Stock at an exercise price of $45 per share (the "2002
Option Grant"). The parties agree that 250,000 of the options granted pursuant

                                      -3-
<PAGE>

to the 2002 Option Grant are vested and that the right to exercise said options
shall expire on February 3, 2009. The remaining 250,000 options that were part
of the 2002 Option Grant have not vested and are of no further force and effect.

                  (b) On April 1, 2003, in accordance with the Stock Option
Agreement attached hereto as Exhibit III, Lane was granted options to purchase
40,000 shares of Common Stock at $11.45 per share (the "2003 Option Grant"). The
parties agree that 20,000 of the 40,000 options granted pursuant to the 2003
Option Grant have vested and that the right to exercise said options shall
expire on February 3, 2009. The remaining 20,000 options that were part of the
2003 Option Grant have not vested and are terminated and are of no further force
or effect.

         6. RETURN OF ANDRX PROPERTY. Lane agrees to return to Andrx no later
than March 31, 2004, any and all property belonging to Andrx, including, without
limitation, codes, home computers, company identification, business credit
cards, and proprietary and confidential information, and Lane shall not retain
any copies, duplicates or excerpts thereof.

         7. RELEASE. In consideration for the payments and benefits set forth
herein and for other valuable consideration, the receipt and adequacy of which
is hereby acknowledged, Lane, for himself, his spouse, heirs, administrators,
children, representatives, executors, successors, assigns, and all other persons
claiming through Lane, if any (collectively, "RELEASERS"), does hereby release,
waive, and forever discharge Andrx, Anda, Inc. (formerly Anda Generics, Inc.),
Andrx Pharmaceuticals, Inc. Andrx Laboratories, Inc., Cybear LLC (formerly
Cybear, Inc.) and all their subsidiaries, affiliates, related organizations, and
all present, past and future employees, officers, agents, directors, attorneys,
successors, and assigns (collectively, the "RELEASEES") from, and does fully

                                      -4-
<PAGE>

waive any obligations of Releasees to Releasers for, any and all liability,
actions, charges, causes of action, demands, damages, or claims for relief,
remuneration, sums of money, accounts or expenses (including attorneys' fees and
costs) of any kind whatsoever, whether known or unknown or contingent or
absolute, including, without limitation, any claim under the Employment
Agreement, which heretofore has been or which hereafter may be suffered or
sustained, directly or indirectly, by Releasers in consequence of, arising out
of, or in any way relating to the Employment Agreement, Lane's employment under
the Employment Agreement or otherwise with Andrx or any of its affiliates and
subsidiaries and the termination of Lane's employment. The foregoing release and
discharge, waiver and covenant not to sue includes, but is not limited to, all
claims and any obligations or causes of action arising from such claims, under
common law including wrongful or retaliatory discharge, breach of contract or
public policy and any action arising in tort including libel, slander,
defamation or intentional infliction of emotional distress, and claims under any
federal, state or local statute including Title VII of the Civil Rights Act of
1964, the Civil Rights Act of 1866 and 1871 (42 U.S.C. ss. 1981), the National
Labor Relations Act, the Age Discrimination in Employment Act (ADEA), the Fair
Labor Standards Act, the Employee Retirement Income Security Act, the Americans
with Disabilities Act of 1990, the Rehabilitation Act of 1973, the Florida
Workers' Compensation Law (F.S.A. ss. 440.01 et seq.), the Florida Employee
Trust Benefit Plans Law (F.S.A. ss. 441.01 et seq.), the Florida Unemployment
Compensation Law (F.S.A. ss. 443.01 et seq.), all Florida General Labor
Regulations (F.S.A. ss. 448.01 et. seq.), the Florida Civil Rights Act (F.S.A.
ss. 760.01 et seq.), or the discrimination or employment laws of any state or
municipality, and/or any claims under any express or implied contract which
Releasers may claim existed with Releasees. This also includes a release by Lane
of any claims for breach of contract, wrongful discharge and all claims for
alleged physical or personal injury, emotional distress relating to or arising

                                      -5-
<PAGE>

out of Lane's employment with Andrx or the termination of that employment; and
any claims under the WARN Act or any similar law, which requires, among other
things, that advance notice be given of certain work force reductions.
Notwithstanding anything contained herein to the contrary, this release and
waiver does not apply to (a) any claims or rights that may arise after the date
Lane signs this Agreement and Release; (b) any right to enforce Lane's rights
under this Agreement and Release; (c) any right Lane may have to indemnification
under the Company's by-laws, articles of incorporation or relevant corporate law
and to receive the benefit of coverage, if any, under liability insurance
policies of any nature maintained by Andrx or its affiliates from time to time
and covering the period during which Lane was employed by Andrx; (d) any right
Lane may have under the Andrx's qualified retirement plans; and (e) any claims
which cannot be waived by law, including without limitation, the right to
participate in an investigation conducted by certain government agencies. Other
than with respect to the foregoing, Lane hereby releases and discharges all
rights, claims, benefits and entitlements arising under the Employment
Agreement.

         Lane waives his right to any monetary recovery should any agency (such
as the Equal Employment Opportunity Commission) pursue any claims on Lane's
behalf. Lane represents and warrants that Lane has not filed any complaint,
charge, or lawsuit against the Releasees with any government agency or any
court.

         8. COVENANT NOT TO SUE. Lane will never sue Releasees in any forum for
any claim covered by the waiver and release language in Paragraph 7 above,
except that Lane may bring a claim under ADEA to challenge this Agreement and
Release. If Lane violates this Agreement and Release by suing Releasees, other
than under ADEA or as otherwise set forth in Paragraph 7 hereof, Lane shall be
liable to the Andrx for its reasonable attorneys' fees and other litigation

                                      -6-
<PAGE>

costs incurred in defending against such a suit. Nothing in this Agreement and
Release is intended to reflect any party's belief that Lane's waiver of claims
under ADEA is invalid or unenforceable, it being the interest of the parties
that such claims are waived.

         9. RESTRICTIVE COVENANTS.

                  9.1 Lane recognizes and acknowledges that the list of Andrx's
customers, as it may exist from time to time, its financial data, and its future
plans and its trade secrets are valuable, special and unique assets of Andrx. At
no time will Lane disclose any such list or information, or any part thereof to
any person, firm, corporation, association or other entity for any unauthorized
reason or purpose whatsoever. In the event of a breach or threatened breach by
Lane of the provisions of this Paragraph 9.1, Andrx shall notify Lane, in
writing, of the nature of Lane's breach of the provisions hereof, and if such
breach is repeated and continuing, Andrx shall be entitled to an injunction
restraining Lane from disclosing, in whole or in part, such list or information,
or from rendering any services to any person, firm, corporation, association or
other entity to whom or which such list or information, in whole or in part, has
been disclosed or is threatened to be disclosed.

                  9.2 For a period of one (1) year following the Effective Date,
Lane covenants and agrees as follows:

                  (a) Lane shall not, without the prior written consent of
Andrx, participate in the management of any Competing Business. For purposes of
this subsection 9.2(a) "Participate" shall mean: (A) holding a position
(including, but not limited to, employee, consultant, principal, member, agent,

                                      -7-
<PAGE>

officer, director, partner or shareholder) in which Lane directly manages such
Competing Business; (B) holding a position (including, but not limited to,
employee, consultant, principal, member, agent, officer, director, partner or
shareholder) in which anyone else who directly manages such Competing Business
is in Lane's reporting chain or chain-of-command, regardless of the number of
reporting levels between them; or (C) providing input, advice, guidance, or
suggestions regarding the management of such Competing Business to anyone
responsible therefor. For purposes of the immediately prior sentence,
"shareholder" shall not mean a less than one percent (1%) shareholder of a
publicly traded company or a less than five percent (5%) shareholder of a
privately held company. "Competing Business" shall mean any business entity or
group of business entities, regardless of whether organized as a corporation,
partnership (general or limited), joint venture, association or other
organization or entity that designs, develops, produces, offers for sale or
sells a product or service that can be used as a substitute for, or is generally
intended to satisfy the same customer needs for, any one or more products or
services (i) in a substantial stage of design or development, (ii) designed or
developed, (iii) manufactured, (iv) produced or (v) offered for sale or sold by
the Andrx business as of the Effective Date.

                  (b) Lane shall not directly or indirectly solicit or encourage
any employee of Andrx who was an employee of Andrx as of the Effective Date, to
leave Andrx or accept any position with any other entity.

                  (c) Lane shall not directly or indirectly contact any
then-existing customers or vendors of Andrx for the purpose of soliciting or
encouraging such customers or vendors to alter their relationship with Andrx in
any way that would be adverse to Andrx.

                  (d) In the event any of the foregoing covenants shall be
determined by any court or arbitrator of competent jurisdiction to be
unenforceable by reason of extending for too great a period of time, over too
great a geographical area or by reason of its being too extensive in any other
respect, it shall be interpreted to extend only over the maximum period of time
for which it may be enforceable, over the maximum geographical area as to which

                                      -8-
<PAGE>

it may be enforceable, and/or to the maximum extent in all other respects as to
which it may be enforceable, all as determined by such court or arbitrator. The
invalidity or enforceability of any particular provision of this Paragraph 9
shall not affect the other provisions hereof, which shall continue in full force
and effect.

                  9.3 Lane acknowledges that Andrx has no adequate remedy at law
and will be irreparably harmed if Lane breaches or threatens to breach the
provisions of Paragraphs 9.1, 9.2(a), 9.2(b) or 9.2(c) of this Agreement and
Release, and, therefore agrees that Andrx shall be entitled to injunctive relief
to prevent any breach or threatened breach of such Paragraphs and that Andrx
shall be entitled to specific performance of the terms of such Paragraphs in
addition to any other legal or equitable remedy it may have, including, without
limitation, recovery of damages from Lane. Nothing in this Agreement shall be
construed as prohibiting Andrx from pursing any other remedies at law or in
equity that it may have or any other rights that it may have under any other
agreement.

         10. NO DUTY TO MITIGATE; SET OFF. Andrx agrees that all times following
the Termination Date, Lane is not required to seek other employment or to
attempt in any way to reduce any amounts payable to Lane by Andrx pursuant to
this Agreement. Further, the amount of the payments provided for in this
Agreement shall not be reduced by any compensation earned by Lane or benefit
provided to Lane as a result of employment by another employer or otherwise.
Andrx's obligations to make the payments provided for in this Agreement and
otherwise to perform its obligations hereunder shall not be affected by any
circumstances, including without limitation, any set off, counterclaim,
recoupment, defense or other right which Andrx may have against Lane.

                                      -9-
<PAGE>

         11. PUBLIC STATEMENTS. Lane will keep confidential and not publish,
disclose, or use or authorize anyone else to publish, disclose or use, without
written authorization by Andrx, the terms or provisions of this Agreement and
Release. Lane and Andrx shall publicly tell persons that Andrx felt that a
change of leadership was in the best interests of Andrx and that the change was
amicable. Lane and Andrx agree that neither party shall at any time engage in
any form of conduct or make any statements or representations that disparage or
otherwise impair the reputation, goodwill or commercial interests of any of the
Releasees or Releasers.

         12. ACKNOWLEDGEMENTS.

         Lane acknowledges and recites that:

                  (a) Lane consents to the filing of an executed copy of this
Agreement with the Securities and Exchange Commission ("SEC") following
expiration of the Revocation Period;

                  (b) Lane will cooperate with Andrx by completing and returning
a Director's Questionnaire to Andrx in connection with Andrx's Proxy Statement
and will promptly complete and return any information required by Andrx in
connection with SEC filings now and in the future;

                  (c) Lane has executed this Agreement and Release knowingly and
voluntarily;

                  (d) Lane has read and understands this Agreement and Release
in its entirety;

                  (e) Lane has been advised and directed orally and in writing
(and this subparagraph (e) constitutes such written direction) to seek legal
counsel and any other advice he wishes with respect to the terms of this
Agreement and Release before executing it, and Lane has in fact received such
advice and retained legal counsel. Stephen T. Lindo, Esq., of Willkie, Farr &
Gallagher represents Lane and has advised Lane in connection with this Agreement
and Release.

                                      -10-
<PAGE>

                  (f) Lane's execution of this Agreement and Release has not
been forced by any employee or agent of Andrx, and Lane has had an opportunity
to negotiate about the terms of this Agreement and Release. LANE HAS BEEN
OFFERED 21 CALENDAR DAYS AFTER RECEIPT OF THIS AGREEMENT AND RELEASE TO CONSIDER
ITS TERMS BEFORE EXECUTING IT. UPON EXECUTION, HE MUST SEND THIS AGREEMENT AND
RELEASE TO THE GENERAL COUNSEL OF ANDRX BY OVERNIGHT MAIL.

         13. REVOCATION PERIOD. LANE SHALL HAVE 7 DAYS FROM THE DATE OF
EXECUTION HEREOF, NOT INCLUDING THE DATE OF EXECUTION ("REVOCATION PERIOD"), TO
REVOKE THIS AGREEMENT AND RELEASE. NOTICE OF REVOCATION SHALL BE GIVEN IN
WRITING BY OVERNIGHT MAIL TO ANDRX'S GENERAL COUNSEL, AS PROVIDED IN PARAGRAPH
14 BELOW, IN WHICH EVENT THIS AGREEMENT AND RELEASE SHALL BE UNENFORCEABLE AND
NULL AND VOID. IN THE EVENT LANE DOES NOT REVOKE THIS AGREEMENT, THE DAY
FOLLOWING THE EXPIRATION OF THE REVOCATION PERIOD IS THE EFFECTIVE DATE HEREOF
("EFFECTIVE DATE").

         14. NOTICES. All notices required to be given under this Agreement and
Release shall be in writing sent certified mail, return receipt requested, or
overnight by United States Express Mail or by a nationally recognized courier
service ("Overnight Mail"), postage prepaid to the addresses of the parties set
forth herein, and if to Andrx, with copies to:

                  Scott Lodin, Esq.
                  General Counsel
                  Andrx Corporation
                  4955 Orange Drive
                  Davie, Florida 33314

and to:
                  Reed Smith LLP
                  599 Lexington Avenue
                  New York, New York 10022
                  Attn:  Herbert F. Kozlov, Esq.

                                      -11-
<PAGE>

and if to Lane with a copy to:

                  Willkie Farr & Gallagher
                  787 Seventh Avenue
                  New York, New York 10019
                  Attn:  Stephen T. Lindo, Esq.

         15. ARBITRATION. Any dispute or controversy between Andrx and Lane,
whether arising out of or relating to this Agreement and Release, the breach of
this Agreement and Release, or otherwise, shall be settled by arbitration
administered by the American Arbitration Association ("AAA") in accordance with
its Commercial Arbitration Rules then in effect, and judgment on the award
rendered by the arbitrator may be entered in any court having jurisdiction
thereof. Any arbitration shall be held before a single arbitrator who shall be
selected by the mutual agreement of Andrx and Lane, unless the parties are
unable to agree to an arbitrator, in which case, the arbitrator will be selected
under the procedures of the AAA. The arbitrator shall have the authority to
award any remedy or relief that a court of competent jurisdiction could order or
grant, including, without limitation, the issuance of an injunction. However,
either party may, without inconsistency with this arbitration provision, apply
to any court having jurisdiction over such dispute or controversy and seek
interim provisional, injunctive or other equitable relief until the arbitration
award is rendered or the controversy is otherwise resolved. Except as necessary
in court proceedings to enforce this arbitration provision or an award rendered
hereunder, or to obtain interim relief, neither a party nor an arbitrator may
disclose the existence, content or results of any arbitration hereunder without

                                      -12-
<PAGE>

the prior written consent of Andrx and Lane. Notwithstanding any choice of law
provision included in this Agreement, the United States Federal Arbitration Act
shall govern the interpretation and enforcement of this arbitration provision.
The arbitration proceeding shall be conducted in Dade or Broward County, Florida
or such other location to which the parties may agree. With respect to a
Non-Payment Claim as defined in Paragraph 16 below, Andrx shall pay the costs of
any arbitrator appointed hereunder and the costs of such arbitration (together
"Arbitration Costs"); provided, however, if Lane is not successful in such
Non-Payment Claim, Lane is obligated to pay one-half of such Arbitration Costs.
With respect to all other arbitrated disputes between the parties, each party
shall pay one-half Arbitration Costs. This Agreement shall constitute a written
agreement to submit any such dispute or controversy to arbitration within the
meaning of the Florida Arbitration Code and shall confer jurisdiction on the
Courts of the State of Florida to enforce such agreement to arbitrate and to
enter judgment on an award in accordance with said Florida Arbitration Code.

         16. ATTORNEY'S FEES. If Lane is the successful party to any arbitration
or litigation between or among any of the parties to this Agreement where such
arbitration or litigation is based upon a claim by Lane of non-payment of
amounts due under Paragraphs 3, 4 or 5 hereof ("Non-Payment Claim"), then Lane
shall be entitled to recovery of reasonable attorney's fees and court costs from
Andrx. If Lane is not the successful party in any Non-Payment Claim, or in the
case of any other claim that is not a Non-Payment Claim in any arbitration or
litigation between or among any of the parties to this Agreement, then court
costs and attorneys' fees incurred by each party shall be borne by the party
incurring such costs.

         17. PAYMENTS IN THE EVENT OF DEATH. In the event Lane dies prior to the
payment of any amounts or receipt of any benefits due and payable under the
terms of this Agreement, any unpaid amounts and/or benefits shall be paid to
Lane's estate.

         18. GOVERNING LAW. This Agreement and Release shall be governed by and
construed in accordance with the internal laws of the State of Florida. Any
arbitration, lawsuits or other proceedings relating to this Agreement and

                                      -13-
<PAGE>

Release or the transactions herein described shall be commenced and held in Dade
or Broward County, Florida or such other location as the parties mutually agree.

         19. GENERAL.

                  19.1 Lane acknowledges that he has no right to any future
employment with Andrx.

                  19.2 This Agreement and Release contains the entire
understanding of the parties relating to subject matter hereof. If may not be
changed orally but only by an agreement in writing signed by the party against
whom enforcement of any waiver, change, modification, extension or discharge is
sought.

                  19.3 The execution of this Agreement and Release shall not be
construed as an admission of any liability whatsoever by Andrx, which liability
is expressly disclaimed by Andrx.

                  19.4 This Agreement and Release shall be binding upon and
inure to the benefit of Andrx, its successors and assigns and Lane and his heirs
and legal representatives.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement and
Release.
         ANDRX CORPORATION

By:  /s/ ANGELO C. MALAHIAS                        /s/ RICHARD J. LANE
      ---------------------------                  --------------------------
Title: PRESIDENT                                   RICHARD J. LANE

Dated:   MARCH 12, 2004                            Dated:   MARCH 12, 2004

                                      -14-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]